{
  "compound": "Nabiximols (THC:CBD 1:1)",
  "condition": "MULTIPLE_SCLEROSIS",
  "effect_size": "Sustained response (OR = 2.8 for continuation)",
  "study_type": "OBSERVATIONAL",
  "source": "NORML:MS_OBSERVATIONAL_001",
  "participants": "1,534 MS patients on nabiximols (national registry)",
  "year": 2017,
  "notes": "Long-Term Safety and Effectiveness of Nabiximols in MS: Italian Registry",
  "confidence": "medium",
  "abstract": "68% responders maintained at 12 months; 72% continued therapy; no tolerance development; effectiveness sustained"
}